Axcynsis Therapeutics key facts
- Developer of antibody-drug conjugate therapies designed for treating cancer.
- Axcynsis Therapeutics’s last known valuation is $36.1M.
- It has raised $21.0M; the latest was Early Stage VC ($6.0M) in Oct 2024.
- Notable investors include Hapi Investment Management, TIBS - Trinity funds.
- Status: Privately Held (backing).
Who backs Axcynsis Therapeutics
2- ·Watch Axcynsis Therapeutics: the Monday email on marks, rounds and moves
Axcynsis Therapeutics funding rounds
No funding rounds for Axcynsis Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Axcynsis Therapeutics valuation
Axcynsis Therapeutics's last known valuation is $36.1 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.
Axcynsis Therapeutics investors
2 investors are on record for Axcynsis Therapeutics, including Hapi Investment Management and TIBS - Trinity funds.
About Axcynsis Therapeutics
Developer of antibody-drug conjugate therapies designed for treating cancer. The company's platform leverages proprietary technologies to create antibody-toxin conjugates, enabling healthcare companies to target the delivery of cytotoxic payloads to cancer cells while minimizing side effects on healthy tissues.
- Sector
- Healthcare
- HQ
- Singapore, Singapore
- Founded
- 2022
- Employees
- 24
- Website
- axcynsis.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Axcynsis Therapeutics’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.